Worth Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Worth Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-100	Closed	-$10.2K	–	464
2023 Q2	$10.2K	Sell	100 -175	-64%	-$16.6K	0.01%	303
2023 Q1	$25K	Hold	275	–	–	0.02%	243
2022 Q4	$10.4K	Hold	275	–	–	0.01%	299
2022 Q3	$7K	Hold	275	–	–	0.01%	319
2022 Q2	$8K	Hold	275	–	–	0.01%	374
2022 Q1	$6K	Buy	+275	New	+$8.16K	﹤0.01%	395

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Worth Asset Management's RETA Position: Q3 2023 in Review

Worth Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 100 shares — an estimated $10.2K sold.

Worth Asset Management first reported a position in RETA in Q1 2022 and held it in 6 quarters. The position peaked at $25K in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Worth Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Worth Asset Management sold 100 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $10.2K.
Worth Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2022 and held it in 6 quarters.
Worth Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $25K in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Worth Asset Management's 13F filing for Q3 2023, filed 11 Oct 2023.